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ABSTRACT
Anti-HBs is a well-known marker of protective capability against HBV. However, little is known about the association
between the qAnti-HBs determined by immunoassays and the neutralization activity (NAT) derived from functional
assays. We developed an in vitro assay for direct measurement of the NAT of human sera. The new assay was highly
sensitive, with an analytical sensitivity of 9.6 ± 1.3 mIU/mL for the HBIG standard. For serum detection, the maximum
fold dilution required to produce ≥50% inhibition (MDF50) of HBV infection was used as the quantitative index. In vitro
NAT evaluations were conducted for a cohort of 164 HBV-free healthy individuals. The results demonstrated that the
NAT positively correlated with the qAnti-HBs (R2 = 0.473, p < 0.001). ROC analysis indicated that the optimal cutoff
value of the qAnti-HBs to discriminate significant NAT (MDF50≥ 8) was 62.9 mIU/mL, with an AUROC of 0.920.
Additionally, we found that the qAnti-HBc was another independent parameter positively associated with the NAT
(R2 = 0.300, p < 0.001), which suggested that antibodies against other HBV proteins generated by previous HBV
exposure possibly also contribute to the NAT. In summary, the new cell-based assay provides a robust tool to analyse
the anti-HBV NAT.
Abbreviations: HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; Anti-HBs: Hepatitis B surface antibody; HBeAg:
Hepatitis B e antigen; Anti-HBc: Hepatitis B core antibody; qAnti-HBs: quantitative hepatitis B surface antibody; qAnti-HBc:
quantitative hepatitis B core antibody; qHBeAg: quantitative hepatitis B e antigen; NAT: neutralization activity; HBIG:
hepatitis B immune globulin; NTCP: Na+-taurocholate cotransporting polypeptide; IRES: internal ribosome entry site;
ccHBV: cell culture derived hepatitis B virus; GE/cell: genome equivalent per cell; MOI: multiplicity of infection; Dpi: day
post infection; HepG2-TetOn: a HepG2-derived cell line that expresses the doxycycline-regulated transactivator; ROC:
receiver operating characteristic curve; AUROC: area under receiver operating characteristic curve; LLOQ: the lower
limits of quantification; MDF50: the maximum fold dilution required to produce ≥50% inhibition; IC50: half maximal
inhibitory concentration
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Introduction
Hepatitis B virus (HBV) infection remains a global
health challenge. According to a recently reported
modelling study, it was estimated that the global preva-
lence of HBsAg in 2016 was 3.9%, corresponding to
approximately 290 million individuals with chronic
HBV infection [1]. HBV infection can induce acute,
fulminant, or chronic hepatitis, liver cirrhosis (LC),
and hepatocellular carcinoma (HCC). More than
700,000 people die due to diseases associated with
HBV infection [2]. Immunoprophylaxis via active
immunization with preventive hepatitis B (HB)
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vaccines and/or passive immunization with hepatitis B
immunoglobulin (HBIG) are effective in preventing
new HBV infection [3]. Although several drugs, includ-
ing interferons and nucleos(t)ide analogs, have been
approved for HBV treatment, a functional cure for
established chronic HBV infection is still difficult to
achieve [3]. Therefore, prevention of HBV infection
by vaccine immunization is regarded as the best way
to eliminate HBV-related diseases [4].
Recombinant hepatitis B small surface antigen (S-
HBsAg, 226 aa) particles are used as the immunogen
in most commonly used HB vaccines to induce preven-
tive anti-HBs antibodies. Antibodies raised by vacci-
nation recognize the conformation-dependent “a”
antigenic loop (AGL) comprising aa110-aa160 of
sHBsAg [5]. According to previous studies, the AGL
region is responsible for the initial interaction between
the virus and cell surface heparin sulfate proteoglycans
[6,7]. Therefore, AGL-directed antibodies generally
exhibit potent neutralization activity similar to that of
antibodies against the viral cellular receptor (NTCP)
binding site (RBD) in the PreS1 region [8,9]. During
the past three decades, the safety and effectiveness of
the sHBsAg-based vaccine was successfully demon-
strated in protecting people from HBV infection and
HBV-related diseases worldwide [10]. Antibodies
specific for sHBsAg raised by vaccination were con-
sidered as the only neutralizing antibody among
these humans who did not have exposure to HBV
infection. In contrast, individuals who recovered from
past HBV infection may have additional neutralizing
antibodies recognizing PreS1 and/or PreS2. For HB vac-
cine immunization, an adequate anti-HBs antibody
response is widely considered to be a titre greater than
or equal to 10 mIU/mL [11], and a booster immunization
is recommended when the titre falls below 10 mIU/mL.
However, due to the absence of a robust in vitro HBV
infection assay, the association between the anti-HBs
binding titre and the neutralization activity (NAT)
remains largely unknown. Moreover, it is unclear
whether there is any NAT difference in between anti-
HBs antibodies derived from vaccination and resolved
natural infection. To address these issues, we developed
a doxycycline (dox)-inducible NTCP-overexpressing
cell line that supports high-efficiency in vitroHBV infec-
tion and therefore enables direct measurement of the
neutralization activity (NAT) of human serum speci-
mens. By using this new assay, we systematically investi-
gated the associations between serological markers and
NAT titres in a well-characterized cohort.
Materials and methods
Plasmids and cells
The cDNA of human sodium taurocholate cotran-
sporting polypeptide (hNTCP) was ligated with an
IRES-driven mCherry (IRES-mCherry) reporter by
PCR. The hNTCP-IRES-mCherry DNA fragment was
subsequently inserted into a pLenti-CMVTRE3G-
eGFP (Addgene 27570) vector. Recombinant lenti-
viruses were produced to transduce HepG2-TetOn
cells (Clontech Laboratories, Otsu, Japan). Stably trans-
duced cells were obtained by flow cytometry cell sort-
ing (FACS) on a BD FACSAria III and further
cultured in the presence of puromycin (3 μg/mL).
After 3 weeks of selection, puromycin-resistant cell
clones were isolated for further evaluation of dox-indu-
cible mCherry expression and PreS1 peptide binding.
For the PreS1 peptide binding assay, cells were incu-
bated with N-terminal myristoylated HBV PreS1
(amino acids 2–48) peptide with C-terminal FITC lab-
elling (customized from Sangon Biotech, Shanghai,
China). One hour after incubation, cells were washed
2–3 times with PBS and analyzed by flow cytometry.
In vitro HBV infection assay
Cell culture-derived HBV (ccHBV) viral stocks for the
infection assay were obtained from the culture medium
of HepAD38 cells as previously described [12,13].
Infectious HBV particles were concentrated from cul-
ture supernatants by precipitation with 5% PEG and
were then resuspended in DMEM supplemented with
10% fetal bovine serum (FBS). The viral titre (genome
equivalent, GE) was determined by a quantitative PCR
assay. For HBV infection, HepG2-TetOn-NTCP cells
were pretreated with 3 μg/mL dox in culture medium
for 3–4 days to induce NTCP expression. Subsequently,
ccHBV was incubated with dox-treated cells at a
defined multiplicity of infection (MOI) in the presence
of 4% PEG 8000 for 24 h, and the cells were then
washed three times with PBS and further cultivated
with dox-containing fresh culture media. During the
culture of HBV-infected cells, the culture media were
collected and refreshed every 2 or 3 days thereafter.
Measurement of NAT in HBIG and human serum
samples
Hepatitis B immune globulin (HBIG) was used as a
standard sample to evaluate the sensitivity and accu-
racy of the NAT assay. For the assay, diluted HBIG
was preincubated with ccHBV in Dox- and PEG-con-
taining culture medium for 1 h, and then the mixture
was then added to dox-treated HepG2-TetOn-NTCP
cells to perform the infection assay. For serum speci-
men tests, the samples were first centrifuged at
13,000 × g for 15 min and sterilized by filtering through
a 0.22 μm filter before incubation with ccHBV and
conduction of cell-based experiments. It should be
noted that if the specimens were initially prepared
and stored in sterilized tube, the filtration sterilization
may be not required. To our experience (data not
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shown), serum filtering through a 0.22 µm filter did not
influence its NAT titre determination.
Immunoassays for HBV markers
For human serum sample quantitative anti-HBs
(qAnti-HBs) measurement, two commercial immu-
noassays were used: one was a chemiluminescent
microparticle immunoassay (Archetect i2000, Abbott
Diagnostics, Abbott Park, IL, USA), and the other
was an ELISA kit (Wantai Biological Pharmacy, Beij-
ing, China). The qAnti-HBc level was measured
using a newly developed double-sandwich immunoas-
say (Wantai Biological Pharmacy, Beijing, China) as
previously described [14]. The levels of the two anti-
body markers were expressed in mIU/mL (qAnti-
HBs) or IU/mL (qAnti-HBc) calibrated using the
WHO standard [15]. Hepatitis B surface antigen
(HBsAg) in the culture supernatants of HBV-infected
cells was quantitatively determined by a microplate
chemiluminescence HBsAg assay (Wantai Biological
Pharmacy, Beijing, China) calibrated using the WHO
HBsAg standard. For hepatitis B e antigen (HBeAg)
measurements, an ELISA-based kit was used (Wantai
Biological Pharmacy, Beijing, China), and values were
expressed with reference to the China National Clinical
Unit (Ncu/mL). The lower limits of quantification
(LLOQ) of the assays in this study were 0.08 IU/mL
for qAnti-HBc, 10 mIU/mL for qAnti-HBs, 0.05 IU/
mL for HBsAg and 0.1 Ncu/mL for HBeAg.
Subjects and cohorts
A cohort consisting of 164 volunteer blood donors was
recruited from the Xiamen Blood Service from 15 to 19
October 2014. All subjects were negative for HBV
(negative in both HBsAg and HBV DNA tests), HCV/
HIV (negative in both anti-HCV/HIV antibody and
HCV/HIV RNA tests), and anti-Treponema pallidum
and had alanine aminotransferase (ALT) levels lower
than the upper limit of normal (40 U/L). Serum samples
from these donors were stored at −20°C until analyzed.
The study was approved by the Institutional Review
Board of the School of Public Health at XiamenUniver-
sity in accordance with the Declaration of Helsinki.
Informed consent was obtained from each subject.
Statistical analysis
Continuous variables such as age, qAnti-HBs, and
qAnti-HBc were compared using an independent
samples t-test. Categorical variables such as sex and
blood type were compared using the Mantel-Haenszel
χ2 test or Fisher’s exact test. Linear regression models
were used for correlation analyses for NAT and other
parameters, such as qAnti-HBs and qAnti-HBc (Pear-
son’s correlation). Statistical analysis was performed
using SPSS (Statistical Package for the Social Sciences)
ver. 21.0 software (SPSS, Chicago, IL, USA). All statisti-
cal analyses were based on 2-tailed hypothesis tests
with a significance level of p < 0.05.
Results
Generation and characterization of HepG2-
TetOn-NTCP cells for HBV infection
To generate HBV-susceptive cells, a dox-inducible
NTCP expression cassette with an IRES-driven
mCherry reporter (Figure 1(A)) was stably transfected
into HepG2-TetOn cells vial lentiviral transduction.
After puromycin selection and single-cell cloning, we
obtained 5 stable HepG2-TetOn-NTCP cell lines
(HepG2-1A4, HepG2-1B3, HepG2-1C2, HepG2-2B1
and HepG2-2B4). After dox-induction, all 5 cell lines
expressed detectable mCherry and showed specific
PreS1-peptide (FITC-conjugated) binding capability
in a dose-dependent manner (Supplemental Figure
1). Flow cytometry analyses revealed that the PreS1-
peptide binding signals of these cells positively corre-
lated with their mCherry expression levels (Sup-
plemental Figure 1). In quantitative comparisons, the
HepG2-2B1 presented the highest mCherry expression
on either percent (%) of fluorescent cells (Figure 1(B),
upper panel) or mean fluorescence intensity (MFI,
Figure 1(B), lower panel). Consistently, the HepG2-
2B1 also showed the best PreS1-peptide binding per-
formance among all test cell lines (Figure 1(C)). In
addition, western blots also demonstrated the dox-trea-
ted 2B1 cells exhibited the highest expression level of
NTCP (for both glycosylated and unglycosylated
protein forms, Figure 1(D)).
In the evaluation of HBV susceptibility (Figure 1(E
and F)), all cell lines successfully supported ccHBV
infection at an MOI of 100 GE/cell, and no significant
difference was observed in postinfection secretions of
either HBeAg (Figure 1(E), lower panel) or HBsAg
(Figure 1(F), lower panel). Comparison of the secretion
levels of the two markers from HepG2-TetOn-NTCP
cell lines at day 5 post infection (dpi 5) revealed that
the average increase in the HBeAg titre (89-fold higher
than the LLOQ) was significantly higher (p < 0.01)
than that in the HBsAg titre (14-fold higher than the
LLOQ). Similar results were noted when comparing
these titres at dpi 9 (HBeAg, 688-fold higher than the
LLOQ; HBsAg, 106-fold higher than the LLOQ; p <
0.01). When the cells were challenged with ccHBV at
an extremely low MOI of 1 GE/cell (Figure 1(E and
F), upper panels), they could also produce detectable
HBeAg (4.3-fold higher than the LLOQ at dpi 9) but
only showed very little HBsAg (1.5-fold higher than
the LLOQ at dpi 9). Although both HBeAg and
HBsAg are routinely used as HBV infection markers,
these results suggested that HBeAg in culture
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supernatants was a more sensitive marker than HBsAg
for evaluating HBV infection in HepG2-TetOn-NTCP
cells. Similarly, other investigators found HepG2 cells
overexpressing NTCP to secrete much more HBeAg
than HBsAg following challenge with ccHBV of geno-
type D [12,16]. Therefore, the HBeAg level in the post-
infection culture supernatant was considered the key
parameter to quantitatively characterize HBV infection
in our further study. Among the 5 cell lines we devel-
oped, as the HepG2-2B1 presented the best perform-
ance on PreS1-peptide binding capability, dox-
inducible NTCP expression level and postinfection
HBeAg secretion level (particularly at low-MOI virus
challenge, Figure 1(E) upper panel), it was selected
to establish the anti-HBV NAT assay in subsequent
study.
Figure 1. Establishment and characterization of NTCP-reconstituted HepG2 cells for in vitro HBV infection. (A) A schematic diagram
depicting the dox-inducible NTCP expression cassette. The NTCP-IRES-mCherry cassette was cloned into the pLenti-CMVTRE3G-
eGFP (Addgene 27570) vector between the BamHI and XbaI restriction sites. (B) Flow cytometric analyses of the dox-induced
mCherry expression of the different HepG2-TetOn-NTCP cell lines. The upper panel showed the percentage of mCherry+ cell popu-
lation, and the lower panel showed the mean fluorescence intensity (MFI) of mCherry+ cell population of various cell lines. (C) Flow
cytometric analyses of the dox-induced PreS1-peptide (FITC conjugated) binding capability of the different HepG2-TetOn-NTCP cell
lines. The upper panel presented the dose-dependent comparison on the FITC/mCherry double positive percentage of different cell
lines, and the lower panel presented the FITC MFI of FITC+/mCherry+ cell populations of various cell lines when binding with myr-
PreS1-FITC peptide at different dosage (500, 100 and 20 nM). (D) Western blots for NTCP expression in the different HepG2-TetOn-
NTCP cell lines with or without dox induction. The NTCP was detected by a commercial rabbit polyclonal antibody against NTCP
(Thermo Fisher Scientific, PA525614). (E, F) Detections of HBeAg (E) and HBsAg (F) in culture supernatants of different HepG2-
TetOn-NTCP cell lines following infection with HBV at 1 GE/cell (upper panel) or 100 GE/cell (lower panel) at dpi 5, 7 and 9. The
FACS analyses, PreS1-peptide binding assay and western blots were performed at 4-day after dox-treatment (3 μg/mL). The
data in panels B, C, E and F are expressed as the means ± SDs. The limits of quantitation for the HBeAg and HBsAg assays used
in our study were 0.1 Ncu/mL and 0.05 IU/mL, respectively. TRE is a tetracycline response promoter; mCherry is a bright red fluor-
escent protein; SLC10A1, solute carrier family 10 member 1, is the gene name of the NTCP protein; IRES is the internal ribosome
entry site; gNTCP, glycosylated NTCP.
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Establishment of an in vitro assay for analyzing
HBV neutralization activity
Figure 2(A) illustrated the detailed procedure of the
HepG2-2B1-based NAT assay. To optimize the assay
performance, we evaluated the infection performance
of HepG2-2B1 cells via ccHBV challenge at different
MOIs (0.25, 1.25, 2.5, 12.5, or 25 GE/cell). The detec-
tion time point for HBeAg secretion was investigated
at dpi 5, 7 and 9. As shown in Figure 2(B), quantifiable
HBeAg (≥0.1 Ncu/mL) was found at dpi 5 in cells that
received an HBV inoculum of ≥2.5 GE/cell. When the
detection time point was extended to dpi 7 or dpi 9,
quantifiable HBeAg levels were observed for HBV
inocula of ≥1.25 GE/cell. To test the influence of the
virus challenge dose on the sensitivity of NAT detec-
tion, we evaluated HBV infection at different MOIs
in the presence of a 2-fold serial dilution of HBIG (a
gradient of 14 concentrations from 2000 mIU/mL to
0.24 mIU/mL). The IC50 (half maximal inhibitory
concentration for HBeAg secretion at dpi 9, Figure 2
(C)) of HBIG to neutralize HBV was approximately
6.8–8.8 mIU/mL in groups that received a virus chal-
lenge of ≤2.5 GE/cell, significantly higher than that of
cells challenged with 12.5 GE/cell (IC50 = 49.0 mIU/
mL) or 25 GE/cell (IC50 = 87.1 mIU/mL). These
results suggested that the analytical sensitivity of the
NAT assay was negatively associated with the HBV
challenge dose. When 1.25 GE/cell was selected as the
standard MOI for the HBIG NAT assay, HBeAg
measurements at dpi 5, 7 and 9 yielded quite similar
dose–inhibition curves (Figure 2(D)). However, ana-
lyses at dpi 9 showed a better goodness-of-fit curve
(R2 = 0.99, Figure 2(D)). Moreover, the average
HBeAg elevation at dpi 9 for a virus challenge of
1.25 GE/cell was 12.5-fold higher than the LLOQ
(1.25 ± 0.08 Ncu/mL), which was higher than that at
dpi 7 (2.6-fold higher than the LLOQ, 0.26 ± 0.04).
Therefore, we ultimately selected an MOI = 1.25 GE/
cell as the HBV challenge dose and dpi 9 as the detec-
tion time point for subsequent NAT measurements.
Under these conditions, we evaluated the reproducibil-
ity of the NAT assay. As the data in Figure 2(E) show,
three independent tests using HBIG samples exhibited
very similar dose–inhibition curves and yielded very
similar IC50 values (9.6 ± 1.3 mIU/mL). These results
suggested good accuracy of the new assay.
Association between the qAnti-HBs titre and the
NAT titre in HBV-free individuals
A total of 164 serum samples from HBV-free individ-
uals (negative for both HBsAg and HBV DNA) were
used to investigate the associations between the anti-
HBV NAT titre and other serological parameters.
The characteristics of these individuals are presented
in Table 1. The qAnti-HBs titres of these samples
were measured with two independent commercial
immunoassays. Correlation analysis revealed good
consistency (R2 = 0.823, p < 0.001, kappa value = 0.84)
between the Architect and Wantai qAnti-HBs assays
(Supplemental Figure 2). Serial two-fold dilutions (2,
4, 8, 16, 32, 64, 128 and 256-fold dilutions in culture
medium) of all samples were made to assess blocking
effects against HBV infection (MOI = 1.25 GE/cell) in
HepG2-2B1 cells. At dpi 9, the levels of secreted
HBeAg were quantified to calculate the NAT titre,
which was defined as the maximum fold dilution
required to produce ≥50% inhibition (MDF50). For
analyses, we divided these individuals into 4 groups
according to their anti-HBs status and anti-HBc status
as shown in Table 1. In either anti-HBc positive (group
A and B) or negative (group C and D) subjects, individ-
uals with detectable anti-HBs always had significantly
higher NAT titres (group A vs. B, p < 0.001; group C
vs. D, p = 0.001). Among anti-HBs positive subjects,
although the average anti-HBs titre was similar (p =
0.50) in between anti-HBc positive (group A) and
negative (group C) individuals, the average NAT titre
was significantly higher in subjects who had detectable
anti-HBc (p = 0.033). Similar results were also noted in
anti-HBs negative donors (p = 0.030). We further com-
pared the NAT titres of vaccinated anti-HBs positive
individuals (n = 34) with nonvaccinated anti-HBc/
anti-HBs double positive ones (n = 14) as shown in
Supplemental Table 1. The results suggested that
although the average anti-HBs binding titre was com-
parable (p = 0.39) between the two groups, the average
NAT titre was higher in nonvaccinated anti-HBc/anti-
HBs double positive individuals than that in vaccinated
anti-HBs positive individuals (1.33 ± 0.60 v.s 0.94 ±
0.62, p = 0.0496). Overall, these results suggested that
the NAT titres not only depend on anti-HBs but also
associate with anti-HBc.
We further analyzed the effect of the qAnti-HBs
level on the distribution of NAT titre by stratifying
all subjects into 5 groups according to their qAnti-
HBs level (as determined by the Architect assay):
<10 mIU/mL (n = 41), 10–50 mIU/mL (n = 31), 51–
200 mIU/mL (n = 28), 201–1000 mIU/mL (n = 42),
>1000 mIU/mL (n = 22). As shown in Table 2, there
were 36 of 41 (87.8%) anti-HBs negative (<10 mIU/
mL) samples had a NAT titre of MDF50 < 8. Among
the remaining 5 samples with discordant results in
the Architect qAnti-HBs assay and the NAT test, 1
sample had a NAT titre of MDF50= 32; this sample
was positive in the Wantai qAnti-HBs assay
(17.8 mIU/mL) and the qAnti-HBc assay (42.3 IU/
mL). The other 4 samples (Architect qAnti-HBs
<10 mIU/mL, NAT MDF50≥ 8) were negative in the
Wantai qAnti-HBs assay; however, 3 of these had
detectable anti-HBc. Only one sample had a NAT
titre of MDF50≥ 8 but was negative in both the Anti-
HBs and Anti-HBc immunoassays. Therefore, the
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specificity of the NAT assay was 97.6% (95% confi-
dence interval, 87.4–99.6%). On the other hand,
among the 123 samples with a qAnti-HBs level greater
than 10 mIU/mL (Architect assay), the NAT titres var-
ied significantly and were widely distributed from 2 to
256 (MDF50 value); 87 of these (70.7%) showed a NAT
titre of MDF50≥ 8 (Table 2). There were 12 (12/31,
38.7%) samples with an anti-HBs titre of 10–50 mIU/
mL and 5 (5/28, 17.9%) samples with an anti-HBs
titre of 51–200 mIU/mL did not show any detectable
NAT activity (MDF50 < 2). In addition, 13 samples
with an anti-HBs titre of 10–50 mIU/mL, 5 sample
with an anti-HBs titre of 51–200 mIU/mL and 1
sample with anti-HBs titre of 201–1000 mIU/mL
only presented very little NAT activity (MDF50 = 2).
In quantitative analyses, we found the NAT titres
were strongly correlated with the qAnti-HBs levels
(R2 = 0.473, p < 0.001, Figure 3(A)) among all subjects
as expected. When ROC analysis was performed to dis-
criminate a NAT titre of MDF50≥ 8 using qAnti-HBs
(Figure 3(B)), the AUROC was 0.920 (95% confidence
interval, 0.876–0.964, p < 0.001), and the optimal cutoff
Figure 2. Establishment of a sensitive HBV neutralization assay in HepG2-2B1 cells. (A) A schematic diagram depicting the exper-
imental procedure of the HBV NAT assay. (B) Comparisons of HBeAg secretion levels of HepG2-2B1 cells infected with ccHBV at
different MOIs (0.25, 1.25, 2.5, 12.5, or 25 GE/cell) at dpi 5, 7 and 9. (C) Tests of the infection-neutralizing potential (inhibition
ratio of HBeAg secretion by HBV-infected HepG2-2B1 cells at dpi 9) of HBIG at various HBV challenge doses (0.25, 1.25, 2.5,
12.5, or 25 GE/cell). (D) IC50 evaluation of the neutralizing potential of HBIG in HepG2-2B1 cells challenged with 1.25 GE/cell
ccHBV at dpi 5, 7, and 9. The R-squared value was introduced to describe the goodness of fit. (E) Evaluation of the reproducibility
of the NAT assay by using HBIG samples in three independent tests. For panels C, D and E, the curves were fitted by nonlinear
regression (log [inhibitor] vs. normalized response).
Table 1. Characteristics of the samples from HBV-free heathy subjects according to the serological anti-HBs and anti-HBc status.
Subgroup
All, n = 164
Anti-HBc(+)a, n = 119 Anti-HBc(−)b, n = 45
P valueAnti-HBs(+)c Anti-HBs(−)d Anti-HBs(+) Anti-HBs(−)
Total A B C D A vs. B C vs. D A vs. C B vs. D
Number (%) 164 (100) 89 (54.3) 30 (18.3) 34 (20.7) 11 (6.7)
Gender, M/F 112/52 57/32 21/9 25/9 9/2 0.66 0.70 0.39 0.69
Age, mean ± SD 26.9 ± 9.5 26.7 ± 9.1 25.8 ± 9.7 27.6 ± 9.9 29.1 ± 11.2 0.65 0.67 0.62 0.35
HB vaccination, n (%) 138 (84.1) 75 (84.3) 22 (73.3) 34 (100) 7 (63.6) 0.19 0.002 0.011 0.70
qAnti-HBs, log10
e 1.72 ± 1.31 2.36 ± 0.76 −0.03 ± 0.84 2.26 ± 0.79 −0.34 ± 0.55 <0.001 <0.001 0.50 0.26
qAnti-HBc, log10
f −0.13 ± 1.11 0.51 ± 0.97 −0.34 ± 0.77 −1.26 ± 0.26 −1.31 ± 0.28 <0.001 0.62 <0.001 <0.001
NAT titre, log10
g 0.97 ± 0.68 1.22 ± 0.67 0.52 ± 0.34 0.94 ± 0.62 0.25 ± 0.35 <0.001 0.001 0.033 0.030
Note: Anti-HBs, antibodies against hepatitis B surface proteins; Anti-HBc, antibodies against the hepatitis B core protein; qAnti-HBs, quantitative Anti-HBs;
qAnti-HBc, quantitative Anti-HBc; NAT, HBV neutralization activity; aAnti-HBc≥ 0.1 IU/mL; bAnti-HBc < 0.1 IU/mL; cAnti-HBs≥ 10 mIU/mL; dAnti-HBs <
10 mIU/mL; emIU/mL (mean ± SD); fIU/mL (mean ± SD); gthe maximum fold dilution required to produce ≥50% inhibition (MDF50), data were mean ± SD.
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was 62.9 mIU/mL, with a sensitivity of 88.0% and a
specificity of 87.5%. As shown in Figure 3(C), the aver-
age NAT titre successively increased (ptrend < 0.001)
with increasing qAnti-HBs levels among the subjects
who had qAnti-HBs level of greater than 50 mIU/mL,
but no significant difference was observed among the
subjects whose qAnti-HBs level was <50 mIU/mL.
Interestingly, we also observed a positive correlation
between NAT titres and qAnti-HBc levels (R2 = 0.300,
p < 0.001, Figure 3(D)). The AUROC of qAnti-HBc
for a NAT titre of MDF50≥ 8 was 0.735 (95% confi-
dence interval 0.656–0.814, p < 0.001), and the optimal
cutoff was 0.43 IU/mL, with a sensitivity of 65.2% and a
specificity of 83.3% (Figure 3(E)). Further analyses
revealed that individuals with a qAnti-HBc level of
≥0.43 IU/mL had significantly higher NAT titres
than those who were anti-HBc negative or had a low
level of qAnti-HBc (<0.43 IU/mL) in the groups with
both high (p = 0.016) and low (p = 0.002) qAnti-HBs
levels (Figure 3(F)).
Discussion
The in vitro HBV neutralization assay is an important
functional test to detect the presence and quantify the
titre of systemic antibodies that prevent HBV infection.
Usually, neutralizing antibodies that can interfere with
the interaction between virus and its host cell receptor
are merely part of a set of virus-specific antibodies in
humans who received vaccine immunization or recov-
ered from past virus infection [17]. Recombinant small
HBsAg-based HBV vaccines have been widely used
and can successfully stimulate neutralizing antibodies
to prevent HBV infection in most individuals [1,4].
Due to the lack of a convenient and sensitive cell-
based neutralization assay, serological tests for deter-
mining the titres of HBsAg-binding specific antibodies
(anti-HBs) by immunoassays are commonly used for
evaluating vaccine-induced protection strength as
well as for indicating recovery and immunity from
resolved HBV infection. However, previous studies
have demonstrated that not all HBsAg-binding reactive
antibodies have neutralizing activity [5]. Although a
qAnti-HBs titre of ≥10 mIU/mL is considered to be
the threshold for HBV seroprotection, the quantitative
association between the qAnti-HBs titre and the NAT
is still largely unknown. Moreover, the HBV NAT
assay is a valuable tool for both virological studies
and antiviral developments for treating HBV infection.
The major obstacle in developing a robust cell-based
HBV NAT assay is the current low-efficiency in vitro
HBV infection system [18]. Several cells and engin-
eered cell lines, including primary human hepatocytes
(PHHs) and primary Tupaia hepatocytes (PTHs), the
HepaRG cell line, and NTCP-overexpressing hepatoma
cell lines (HepG2-NTCP and Huh7-NTCP), have been
demonstrated to be HBV-susceptible [16,19,20]. How-
ever, the infection efficiency and cell source of primary
hepatocytes are limited, and HepaRG cells require a
time-consuming differentiation culture process
(approximately 4 weeks) [21]. In recent years, NTCP-
overexpressing hepatoma cells have been an important
advancement in the development of high-throughput
infection assays, but it is important to note that a
high-MOI (ranging from 100 to 10,000) virus challenge
is still required to attain acceptable infection levels for
nearly all of the previously reported NTCP-reconsti-
tuted hepatoma cell lines [16,18–20]. For the NAT
assay, a high-MOI virus challenge greatly reduces the
analytical sensitivity for the detection of neutralizing
antibodies (Figure 2(C)). As qAnti-HBs levels vary sig-
nificantly and are widely distributed among humans, a
robust assay for the direct measurement of the NAT
titre in serum specimens should support HBV infection
in challenges with low-MOI viral inocula. In this study,
we established a new HepG2 cell clone (HepG2-2B1)
allowing dox-regulated expression of human NTCP.
In these cells, the dox-inducible NTCP expression cas-
sette was stably integrated into the HepG2 cell genome
downstream of an IRES-mCherry reporter, therefore
enabling FACS selection of cell clones with high
expression levels of NTCP via the evaluation of
mCherry fluorescence. The HepG2-2B1 cell clone
showed more stable and higher levels of NTCP
expression (Figure 1(D)) and PreS1-peptide binding
capability (Figure 1(C)), which possibly contributed
to its better infection performance than that of the
other clones, particularly in cells infected with a low-
MOI HBV inoculum (Figure 1(E and F)). By using
this HepG2-2B1-based infection system, we investi-
gated the optimal virus inoculum dose (1.25 GE/cell)
and detection time point (dpi 9) for neutralization
Table 2. The distribution of NAT titres among the 164 serum samples according to the qAnti-HBs strata.
qAnti-HBs strata
Neutralizing Antibody Titer (NAT) strata
Total<2 4 8 16 32 64 128 256
\lt 10 mIU/mL 14(7/7) 22(19/3) 4(3/1) 0 1(1/0) 0 0 0 41(30/11)
10–50 mIU/mL 12(9/3) 13(7/6) 4(3/1) 0 1(1/0) 1(1/0) 0 0 31(21/10)
51–200 mIU/mL 5(2/3) 5(3/2) 12(8/4) 2(2/0) 1(1/0) 3(3/0) 0 0 28(19/9)
201–1000 mIU/mL 0 1(1/0) 3(1/2) 10(7/3) 8(8/0) 15(13/2) 3(3/0) 2(2/0) 42(35/7)
>1000 mIU/mL 0 0 1(1/0) 2(2/0) 8(4/4) 5(2/3) 5(4/1) 1(1/0) 22(14/8)
Total 31(18/13) 41(30/11) 24(16/8) 14(11/3) 19(15/4) 24(19/5) 8(7/1) 3(3/0) 164(119/45)
Note: The data were number (Anti-HBc-positive no./Anti-HBc-negative no.). The NAT was defined as the maximum fold dilution required to inhibit HBeAg
secretion by ≥50% (MDF50) in HepG2-2B1 cells infected with 1.25 GE/cell ccHBV at day 9 post-infection.
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analysis and established a robust NAT assay (Figure 2).
The new assay showed excellent analytical sensitivity
(9.6 ± 1.3 mIU/mL of HBIG equivalent) and good
accuracy (Figure 2(E)), therefore providing a possible
tool enabling the direct measurement of human
serum samples. On the other hand, unlike other cells
with exogenous NTCP expression driven by constitu-
tive promoter, HepG2-2B1 allows tightly regulable
NTCP expression by dox. As the strength of TRE3G
promoter is highly dox dose-dependent, the new cell
line may enable to control the NTCP at various levels,
giving more flexibility over other constitutively NTCP-
expressing systems.
We quantitatively analyzed the relationship between
HBV serological markers and serum NAT titres in a
cohort of HBV-free healthy donors. As expected, our
data revealed a strong positive correlation between
the qAnti-HBs and NAT titres (Figure 3(A), R2 =
0.473). However, 29.3% (36/123) of persons with
qAnti-HBs≥ 10 mIU/mL (ranging from 10.7 to
202.3 mIU/mL) did not present significant NAT
activity (MDF50≥ 8). Among these subjects, 17 showed
no detectable NAT (MDF50 < 2) and the remaining 19
had very little NAT (MDF50= 4) (Table 2). These
results suggested that some human anti-HBs anti-
bodies might not be able to block HBV infection
Figure 3. Association between the functional HBV neutralization titre and binding titres of anti-HBs and anti-HBc in sera from HBV-
free heathy donors. (A) Correlation between the NAT and qAnti-HBs titres. (B) ROC analysis of the qAnti-HBs level to discriminate
significant HBV-neutralizing activity (MDF50≥ 8 in NAT assay). (C) Average serum NAT titres in HBV-free subjects according to the
qAnti-HBs stratum. (D) Correlation between the NAT and qAnti-HBc titres. (E) ROC analysis of the qAnti-HBc level to discriminate
significant HBV-neutralizing activity (MDF50≥ 8 in the NAT assay). (F) Average serum NAT titres in HBV-free subjects according to
the qAnti-HBs and qAnti-HBc strata. ROC, receiver operating characteristic curve; AUROC, area under the ROC curve.
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although they can bind to HBsAg proteins. As most of
these samples (25/36, 69.4%) had a relatively low anti-
HBs titre (10–50 mIU/mL), the low-affinity of anti-
bodies existing in such samples may be one possible
reason for the NAT absence. There was one sample
with a high anti-HBs titre of 202.3 mIU/mL showing
very little NAT activity (MDF50 = 4). As this sample
is anti-HBc seropositive, its low NAT activity may be
attributed to past infection with a virus which had
mutated surface proteins and was different than
ccHBV used our assay. Notably, a recent study demon-
strated that a qAnti-HBs titre of 56.48 mIU/mL is a
protective threshold (hazard ratio = 8.48) for HBV
reactivation risk in patients with lymphoma and
resolved HBV infection receiving rituximab-containing
chemotherapy [22]. Our analyses suggested that an
optimal cutoff value of the qAnti-HBs level to discrimi-
nate significant NAT (MDF50≥ 8) was 62.9 mIU/mL,
which was quite similar to the newly determined pro-
tective threshold for HBV reactivation, and both of
these values were much higher than the commonly
used protective threshold (10 mIU/mL). These results
suggested that sufficient HBV protective immunity
may require a higher anti-HBs binding titre, possibly
greater than 50–60 mIU/mL. Interestingly, our ana-
lyses revealed that the anti-HBs and anti-HBc double
positive donors had similar anti-HBs titres but showed
significantly higher NAT titres than those who were
anti-HBs positive but anti-HBc negative (Table 1).
Moreover, the qAnti-HBc level was also independently
associated with serum NAT (R2 = 0.300, p < 0.001,
Figure 3(D)). Because anti-HBc is a serological marker
of past, resolved HBV infection, it is possible that the
appearance of anti-HBc is a proxy for anti-HBV immu-
nity derived from non-HBsAg neutralizing antibodies
(such as PreS1/PreS2-specific antibodies). This hypoth-
esis warrants further study to determine whether there
is an association between serum NAT activity and
PreS1/PreS2-specific antibodies among anti-HBc posi-
tive individuals. On the other hand, the possibility that
a high titre of anti-HBc antibody has direct HBV-neu-
tralization activity or a potential interference effect on
the current NAT assay cannot be entirely excluded.
To our knowledge, this study is the first to develop a
cell-based assay enabling measurements of HBV NAT
in human serum samples. By using this new assay, we
provided direct evidence for the relationship between
the anti-HBs binding titre and functional activity in
HBV-free healthy persons. A limitation of our study
is the low case number, and our findings need to be
confirmed in a larger cohort. In addition, we just eval-
uated the assay performance in HBV-free heathy indi-
viduals but not in HBV patients. Further
improvements may be required for its real clinical
application. Nevertheless, our study provides a versatile
platform for testing the efficacy of new drug candidates,
as well as a valuable tool for analyzing functional
antibodies of clinical samples, in particular for patients
with coexisting HBsAg and anti-HBs.
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